Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the intent to grant European Patent 14784945.9, entitled "Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease," was received from the European Patent Office. The European registration once formally granted will add ... Full story available on